Inozyme Pharma (NASDAQ:INZY – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Zacks.com reports. The brokerage currently has a $4.50 price target on the stock. Zacks Investment Research‘s price target suggests a potential upside of 13.35% from the stock’s previous […]
Inozyme Pharma (NASDAQ:INZY – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The brokerage presently has a $4.50 target price on the stock. Zacks Investment Research‘s price objective would indicate a potential upside of 8.17% from the company’s current […]
Inozyme Pharma, Inc. (NASDAQ:INZY – Get Rating) COO Henric Bjorn Bjarke bought 27,100 shares of the firm’s stock in a transaction that occurred on Tuesday, April 19th. The stock was bought at an average price of $3.69 per share, with a total value of $99,999.00. Following the completion of the acquisition, the chief operating officer […]